Use of nonsteroidal antiinflammatory drugs and distal large bowel cancer in whites and African Americans

American Journal of Epidemiology

Volumn 168, Issue 11, 2008, Pages 1292-1300

  Kim, Sangmi ^a,d   Martin, Christopher ^b   Galanko, Joseph ^b   Woosley, John T ^b   Schroeder, Jane C ^a   Keku, Temitope O ^b   Satia, Jessie A ^a   Halabi, Susan ^c   Sandler, Robert S ^a,b  

^a The University of North Carolina at Chapel Hill   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Anti inflammatory agents, non steroidal; Colonic neoplasms; Colorectal neoplasms; Intestine, large; Population groups; Rectal neoplasms

Indexed keywords

ACETYLSALICYLIC ACID; ANACIN; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; EXCEDRIN; IBUPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN; PIROXICAM; ROFECOXIB;

CANCER; DIGESTIVE SYSTEM; DRUG; RACE; RISK FACTOR; TUMOR;

ADENOCARCINOMA; ADULT; AFRICAN AMERICAN; AGED; ARTICLE; CHEMOPROPHYLAXIS; COLON ADENOCARCINOMA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ASSOCIATION; EUROPEAN AMERICAN; FEMALE; GENETIC HETEROGENEITY; HUMAN; LARGE INTESTINE CANCER; MAJOR CLINICAL STUDY; MALE; RACE; RECTUM CARCINOMA; SIGMOID CARCINOMA; TUMOR LOCALIZATION; UNITED STATES;

ADULT; AFRICAN AMERICANS; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2 INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; MALE; MIDDLE AGED; NORTH CAROLINA;

EID: 57149090716     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwn255     Document Type: Article

References (47)

1. Rosenberg L, Louik C, Shapiro S. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer. 1998;82(12):2326-2333.
2. Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer. 1993;72(4):1171-1177.
3. Peleg II, Maibach HT, Brown SH, et al. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med. 1994;154(4):394-399.
4. Muscat JE, Stellman SD, Wynder EL. Nonsteroidal anti-inflammatory drugs and colorectal cancer. Cancer. 1994;74(7):1847-1854.
5. Reeves MJ, Newcomb PA, Trentham-Dietz A, et al. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev. 1996;5(12):955-960.
6. La Vecchia C, Negri E, Franceschi S, et al. Aspirin and colorectal cancer. Br J Cancer. 1997;76(5):675-677.
7. Friedman GD, Coates AO, Potter JD, et al. Drugs and colon cancer. Pharmacoepidemiol Drug Saf. 1998;7(2):99-106.
8. Coogan PF, Rosenberg L, Louik C, et al. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes Control. 2000;11(3):249-255.
9. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121(4):241-246.
10. Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333(10):609-614.
11. Smalley W, Ray WA, Daugherty J, et al. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med. 1999;159(2):161-166.
12. Langman MJ, Cheng KK, Gilman EA, et al. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database. BMJ. 2000;320(7250):1642-1646.
13. Collet JP, Sharpe C, Belzile E, et al. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer. 1999;81(1):62-68.
14. Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol. 2004;88(4):261-266.
15. Lindblom A. Different mechanisms in the tumorigenesis of proximal and distal colon cancers. Curr Opin Oncol. 2001;13(1):63-69.
16. Demers RY, Severson RK, Schottenfeld D, et al. Incidence of colorectal adenocarcinoma by anatomic subsite. An epidemiologic study of time trends and racial differences in the Detroit, Michigan area. Cancer. 1997;79(3):441-447.
17. Nelson RL, Dollear T, Freels S, et al. The relation of age, race, and gender to the subsite location of colorectal carcinoma. Cancer. 1997;80(2):193-197.
18. Aldrich TE, Vann D, Moorman PG, et al. Rapid reporting of cancer incidence in a population-based study of breast cancer: one constructive use of a central cancer registry. Breast Cancer Res Treat. 1995;35(1):61-64.
19. Weinberg CR, Sandler DP. Randomized recruitment in case-control studies. Am J Epidemiol. 1991;134(4):421-432.
20. Ainsworth BE, Haskell WL, Leon AS, et al. Compendium of physical activities: classification of energy costs of human physical activities. Med Sci Sports Exerc. 1993;25(1):71-80.
21. Applied Research Program, National Cancer Institute. Diet History Questionnaire, Version 1.0. Bethesda, MD: National Cancer Institute; 2007.
22. Botting RM. Mechanism of action of acetaminophen: is there a cyclooxygenase 3? Clin Infect Dis. 2000;31(suppl 5):S202-S210.
23. Marnett LJ, Dubois RN. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002;42:55-80.
24. Gasparini G, Longo R, Sarmiento R, et al. Inhibitors of cyclooxygenase 2: a new class of anticancer agents? Lancet Oncol. 2003;4(10):605-615.
25. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part II). J Natl Cancer Inst. 1998;90(21):1609-1620.
26. Zha S, Yegnasubramanian V, Nelson WG, et al. Cyclooxygenases in cancer: progress and perspective. Cancer Lett. 2004;215(1):1-20.
27. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94(4):252-266.
28. Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003;348(10):883-890.
29. Baron JA, Cole BF, Sandler RS, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348(10):891-899.
30. Dube C, Rostom A, Lewin G, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007;146(5):365-375.
31. Gann PH, Manson JE, Glynn RJ, et al. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993;85(15):1220-1224.
32. Cook NR, Lee IM, Gaziano JM, et al. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA. 2005;294(1):47-55.
33. Cohen JS. Why aren't lower, effective, OTC doses available earlier by prescription? Ann Pharmacother. 2003;37(1):136-142.
34. Sansbury LB, Millikan RC, Schroeder JC, et al. Use of nonsteroidal antiinflammatory drugs and risk of colon cancer in a population-based, case-control study of African Americans and Whites. Am J Epidemiol. 2005;162(6):548-558.
35. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999;340(24):1888- 1899.
36. Martin C, Connelly A, Keku TO, et al. Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas. Gastroenterology. 2002;123(6):1770-1777.
37. Lin HJ, Lakkides KM, Keku TO, et al. Prostaglandin H synthase 2 variant (Val511Ala) in African Americans may reduce the risk for colorectal neoplasia. Cancer Epidemiol Biomarkers Prev. 2002;11(11):1305-1315.
38. Macarthur M, Sharp L, Hold GL, et al. The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1613-1618.
39. Sansbury LB, Bergen AW, Wanke KL, et al. Inflammatory cytokine gene polymorphisms, nonsteroidal anti-inflammatory drug use, and risk of adenoma polyp recurrence in the Polyp Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2006;15(3):494-501.
40. Mahipal A, Anderson KE, Limburg PJ, et al. Nonsteroidal anti-inflammatory drugs and subsite-specific colorectal cancer incidence in the Iowa Women's Health Study. Cancer Epidemiol Biomarkers Prev. 2006;15(10):1785-1790.
41. Chan AT, Ogino S, Fuchs CS. Aspirin and the risk of colorectal cancer in relation to the expression of COX-2. N Engl J Med. 2007;356(21):2131- 2142.
42. Dimberg J, Samuelsson A, Hugander A, et al. Differential expression of cyclooxygenase 2 in human colorectal cancer. Gut. 1999;45(5):730-732.
43. Joo YE, Kim HS, Min SW, et al. Expression of cyclooxygenase-2 protein in colorectal carcinomas. Int J Gastrointest Cancer. 2002;31(1-3):147-154.
44. West SL, Savitz DA, Koch G, et al. Recall accuracy for prescription medications: self-report compared with database information. Am J Epidemiol. 1995;142(10):1103-1112.
45. Psaty BM, Koepsell TD, Lin D, et al. Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc. 1999;47(6):749-754.
46. American Cancer Society. Incidence and Mortality Rates by Site, Race, and Ethnicity, US, 1999-2003. Atlanta, GA: American Cancer Society; 2007. (http://www.cancer.org/downloads/stt/CFF2007IncidenceMortRates.pdf). (Accessed July, 2008).
47. Paulose-Ram R, Hirsch R, Dillon C, et al. Prescription and non-prescription analgesic use among the US adult population: results from the third National Health and Nutrition Examination Survey (NHANES III). Pharmacoepidemiol Drug Saf. 2003;12(4):315-326.